Musculo-skeletal disorders
7 results
Applied filters
Preparing to use ustekinumab biosimilar
31 July 2026Introducing biosimilar ustekinumab needs planning. Work with the multidisciplinary team to ensure familiarity with the area and develop an implementation plan.
The licence and supporting evidence for ustekinumab biosimilars
31 July 2026Ustekinumab biosimilars are available for use within the NHS. Learn about indications, formulations, supporting evidence and differences.
Preparing to use golimumab biosimilar
21 July 2026One golimumab biosimilar (Gobivaz) is available. We offer general information and implementation advice.
The licence and supporting evidence for golimumab biosimilar
2 June 2026We highlight evidence for available golimumab biosimilar(s) and differences between the biosimilar(s) and the reference product (Simponi).
The licence and supporting evidence for denosumab 60mg biosimilars
24 April 2026Denosumab 60mg biosimilars are licensed. Learn about indications, formulations, supporting evidence and differences.
The licence and supporting evidence for tocilizumab biosimilar
6 March 2026Two licensed tocilizumab biosimilars are available: Tyenne and Avtozma. Learn about the licensed indications, supporting evidence and key differences.
Preparing to use tocilizumab biosimilar
6 March 2026Two tocilizumab biosimilars are now available. We offer general information and implementation advice.